Publications To Date


    Filter Publications

    PAGE 1 OF 8 | DISPLAYING 1 - 15 OF 110 RESULTS

    Dhage S. et. al., A genomic ruler to assess oncogenic transition between breast tumor and stroma, 10.1371/journal.pone.0205602, PLoS ONE, Oct 16, 2018

    Roszik J. et. al., Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy, 10.3389/fimmu.2018.02102, Front. Immunol, Sep 19, 2018

    Foulds G.A. et. al., Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer, 10.3389/fimmu.2018.02028, Front Immunol., Sep 11, 2018

    Su B. et. al., hsa-miR-24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c-Myc/epithelial-mesenchymal transition axis, 10.3892/or.2018.6690, Oncol Rep., Sep 07, 2018

    Sugio T. et. al., Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS, 10.1182/bloodadvances.2018018754, Blood Adv., Sep 07, 2018

    Rodrigues D.N. et. al., Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer, 10.1172/JCI121924, JCI, Sep 04, 2018

    Yuan X. et. al., GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression,, Oncogene, Sep 04, 2018

    Jiang P. et. al., Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response,, Nature Med., Aug 20, 2018

    Dhawan D. et. al., Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer, 10.1371/journal.pgen.1007571, PLoS Genetics, Aug 08, 2018

    Kim S-S. et. al., Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor, 10.1080/2162402X.2018.1484982, Oncoimmunology, Aug 01, 2018

    Ghaffari A. et. al., STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer,, Br. J. Cancer, Jul 26, 2018

    Cottagiri M. et. al., In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity,, Cellular & Molecular Immunology , Jul 20, 2018

    Niyongere S. et. al., Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML,, Leukemia, Jul 19, 2018

    Crawford G. et. al., Epithelial damage and tissue γδ T cells promote a unique tumor-protective IgE response,, Nature Immunology, Jul 16, 2018

    Wolf G.T. et. al., IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers, 10.2147/OTT.S165411, Onco. Targets. Ther., Jun 28, 2018